SRTS Q3'26 Earnings: revenue estimate is 6.61M USD

Sensus Healthcare (SRTS) will report Q3'26 earnings on October 29. Analysts expect revenue of $6.61M and EPS of -$0.06. The announcement is scheduled for 8:00 AM ET.

Original reporting
Published Oct 22, 2026, 11:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 11:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SRTS Q3'26 Earnings: revenue estimate is 6.61M USD — source image
Decision brief

The 30-second read

$SRTSNeutralLow
01

Why it matters

The preview sets expectations but does not provide new material information.

02

Market read

Earnings preview of a small‑cap biotech; limited trading relevance until actual results.

03

What to watch

Potential hidden catalysts such as new product launches or regulatory updates not mentioned.

Relevance 4/10Novelty 3/10Timing: pre‑market today

Background

Sensus Healthcare is a micro‑cap biotech listed on NASDAQ under SRTS.

Company-level read

Ticker impact

$SRTSNeutralMedium confidence
Context

Article previews Sensus Healthcare's Q3'26 earnings with revenue estimate of $6.61M and EPS of -$0.06, scheduled for release Oct 29.

Expected impact

likely modest pressure as investors await actual results

Evidence & confidence

No new earnings data, only estimates; traders may hold positions until the actual release.

Market effects

Limited impact on healthcare sector; small‑cap earnings preview.

US market focus due to NASDAQ listing.

Low

Counterpoint

If the company beats the modest estimate, the stock could rally sharply.

Key entities

  • Sensus Healthcare, Inc.

    US‑listed biotech company reporting Q3'26 earnings.

Related articles

$SRTSMed

Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights

Sensus Healthcare, Inc. (SRTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights Commercial Momentum Builds with Broader Physician Engagement and Customer Adoption New Dermatology Group Relationships Support Customer Expansion and Diversification Strategy Incre

$SRTSMed

Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights

Sensus Healthcare, Inc. (SRTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights Commercial Momentum Builds Following CPT Code Implementation Revenue Recognition on Eight Purchased Units Shifted to Q3 Due to Financing Approval Timing CMS Proposed 26% Increase

$AGROHighAI 8/10

Adecoagro (AGRO) Q3 2026 Earnings Call Transcript

Adecoagro reported Q3 2026 earnings, with gross sales of $591M and year-to-date sales of $1.5B. Fertilizers drove growth, offsetting lower Sugar, Ethanol, and Energy revenues. Adjusted EBITDA reached a 9-month high. The company acquired the Caarapó mill, expecting it to boost crushing volumes. Fertilizers and Food/Agriculture segments performed strongly, while Sugar/Ethanol faced cost pressures and lower sales.

$FIGRHighAI 8/10

Figure Tech (FIGR) Q3 2026 Earnings Call Transcript

Figure Tech (FIGR) reported Q3 2026 earnings with $5.8B volume, up 107% YoY, and 58% EBITDA margin. The company processed $5.1B organically and $0.7B from Kiavi. Figure Connect accounted for 72% of volume. They added 612 partners, expanded SMB business to $500M run rate, and launched new AI-driven products. Kiavi acquisition added $8B volume and new asset classes, expected to be accretive. The company saw resilience in higher interest rates, with strong investor demand and securitizations.

$CDNLMedAI 8/10

Cardinal Infra (CDNL) Q3 2026 Earnings Call Transcript

Cardinal Infra (CDNL) reported Q3 2026 revenue of $202M, up 65%, but adjusted EBITDA fell to $9M from $21M YoY. The company withdrew full-year guidance due to project estimate revisions and operational challenges. The board authorized a $50M share repurchase program. CFO Mike Rowe will step down, and the company is focusing on improving execution and profitability.